Q: I haven't seen too many company purchases similar to GUD buying GBT. Is it unusual to take out the major shareholders then individuals and will small shareholders be forced to sell?
The purchase was paid in cash with no dilution, Medisen is paying $77M for their shares, GUD will have well over $300M left plus any Biotoscana profits from Nov. 29 and, yet the share price is very weak. Is something not going well?
Finally, Medisen has 4 years to sell their GUD shares. Do you think they are selling now to raise cash to buy back their shares and, second, is a low price good for GUD as biotoscan shareholders will most likely sell at the ptemium offered? Thank you!
The purchase was paid in cash with no dilution, Medisen is paying $77M for their shares, GUD will have well over $300M left plus any Biotoscana profits from Nov. 29 and, yet the share price is very weak. Is something not going well?
Finally, Medisen has 4 years to sell their GUD shares. Do you think they are selling now to raise cash to buy back their shares and, second, is a low price good for GUD as biotoscan shareholders will most likely sell at the ptemium offered? Thank you!